Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from underinvestment and significant manufacturing deficiencies [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its infant formula business and its financial results during the specified class period [1]. Allegations - The complaint claims that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs [1]. - Perrigo is alleged to have needed to make substantial capital and operational expenditures beyond the company's stated cost estimates to remediate the infant formula business [1]. - There were significant manufacturing deficiencies identified in the facility for the infant formula business [1]. - As a result of these issues, the company's financial results, including earnings and cash flow, were overstated [1]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - The class period for the lawsuit is from February 27, 2023, to November 4, 2025 [1]. - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses due to misleading statements or omissions [3].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its infant formula business acquired from Nestlé [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchases made between February 27, 2023, and November 4, 2025 [1]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Perrigo - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant was plagued by significant underinvestment and operational deficiencies [3]. - Specific claims include the need for substantial capital expenditures beyond initial estimates to address these issues, leading to overstated financial results [3]. Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, resulting in a 50% decline in earnings per share compared to the previous year [4]. - Following this announcement, Perrigo's stock price fell over 15% [4]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, leading to a nearly 10% drop in stock price [5]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing an 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, resulting in a stock price drop of over 25% [7]. Company Background - Perrigo provides over-the-counter health and wellness solutions and has been involved in significant acquisitions to expand its product offerings [2].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Perrigo Company plc, alleging misrepresentations related to its infant formula business acquired from Nestlé, affecting investors who purchased securities between February 27, 2023, and November 4, 2025 [3]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who acquired Perrigo securities during the specified period [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Perrigo and certain senior officers [3]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file necessary documents by January 16, 2026 [4]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [5].

Group 1: Lululemon and Costco - Lululemon announced the departure of CEO Calvin McDonald, effective end of January, with interim leadership in place while searching for a permanent successor [1] - Lululemon reported better-than-expected earnings for Q3, but has been underperforming for over a year, with shares up more than 9% following the earnings report [2] - Costco exceeded Wall Street forecasts for its first quarter, driven by e-commerce growth, with Black Friday marking a record-breaking day for its digital business [2] Group 2: Disney and OpenAI - Disney made a $1 billion equity investment in OpenAI, allowing users on OpenAI's Sora platform to create content featuring Disney's copyrighted material, including over 200 characters [3][4] - Disney CEO Bob Iger stated that the deal provides a pathway into AI and helps reach younger consumers, while OpenAI CEO Sam Altman mentioned there will be restrictions on the use of Disney characters in Sora videos [4] Group 3: Fiber Market Trends - There is a growing consumer focus on fiber, with 22% of shoppers listing high fiber content as a top-three factor when shopping, up from 17% four years ago [9] - Companies like Coca-Cola and Nestlé are launching fiber-focused products, and PepsiCo plans to introduce high-fiber versions of Smartfood and SunChips next year [9]

Core Viewpoint - General Mills, Inc. is facing a downward revision in its stock price target and is expected to report a decline in earnings and revenues in the upcoming quarter [1][3]. Company Overview - General Mills is a leading global food company known for brands like Cheerios and Yoplait, competing in the consumer packaged goods industry against companies like Kellogg's and Nestlé [1]. - The company has a market capitalization of approximately $25.42 billion and a trading volume of 4,693,176 shares [5]. Stock Performance - As of the announcement, General Mills' stock was trading at $46.32, which is 1.47% below the new price target of $47 set by Jefferies [2]. - The stock has fluctuated between $45.82 and $46.70 during the day's trading, currently priced at $46.24, reflecting a 1.15% increase today, or $0.53 [2][5]. - Over the past year, the stock has seen a high of $67.35 and a low of $45.15, indicating significant volatility [5]. Earnings Outlook - Analysts expect a decline in earnings and revenues for the quarter ending November 2025, with the upcoming earnings report set for December 17 being crucial for the stock's price movement [3]. - Management will address business conditions during the earnings call, which will be key in evaluating the sustainability of any immediate price changes [4]. - Investors are particularly interested in any signs of a positive earnings per share (EPS) surprise, which could boost the stock's performance [4].

[applaudissements] avril 2023, je suis au Guatemala avec mes enfants et ma femme enceinte. Chaud, un regeton qui vibre à fond dans la voiture. On roule sur une piste en direction de la mer des Caraïbes.Autour forêt tropicale, quelques plantations de bananes et de café. Quand soudain je vois des bras qui s'agitent au devant, je vois des hommes qui tirent un câble au travers de la route. Je plante les freins dans un nuage de poussière.Les hommes s'approchent, sont des paysans. Peste la vitre, il me demande de ...

Core Insights - PepsiCo is a leading player in the food and beverage industry, with a diverse product portfolio including brands like Pepsi, Mountain Dew, and Lay's, competing against giants like Coca-Cola and Nestlé [1] - Barclays has set a price target of $144 for PepsiCo, while the stock is currently trading at $149.70, which is 3.81% above the target [1][6] Strategic Changes - PepsiCo is implementing significant changes driven by Elliott Investment Management's push for cost-cutting and product streamlining, planning to cut nearly 20% of its SKUs in the U.S. by early 2026 [2][6] - The company is not eliminating entire product lines but is focusing on specific versions, such as different sizes, flavors, or package types, to maintain core offerings while optimizing for efficiency [3][6] Product Development and Pricing Strategy - PepsiCo aims to offer more affordable pricing options to boost growth and increase purchase frequency of its mainstream brands [4] - The company is rapidly launching new products that cater to consumer demands for healthier options, including those without artificial colors and flavors, and those with more protein, fiber, and whole grains [4][6] Market Performance - Currently, PepsiCo's stock is trading at $149.70, reflecting a $5.06 or 3.50% increase, with a daily trading range between $147 and $149.71 and a market cap of approximately $204.7 billion [5]

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc and certain officers for alleged violations of federal securities laws during the specified class period from February 27, 2025, to November 4, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Perrigo securities during the class period [2] - The Complaint alleges that Defendants made materially false and misleading statements and failed to disclose adverse facts about the Company's business and operations [3] - Specific allegations include significant underinvestment in the infant formula business acquired from Nestlé, the need for substantial capital expenditures, and manufacturing deficiencies [8] Group 2: Investor Participation - Investors who suffered losses in Perrigo have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Participation in any recovery does not require serving as lead plaintiff [3] Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only be reimbursed for expenses if successful [4] - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [5]

Core Insights - Elevance has appointed Amy Schulman, a former Pfizer executive, to its board of directors as part of its strategy to enhance its pharmacy services [3][8] - Schulman brings extensive experience in the healthcare sector, including her roles at Pfizer and her current position at Polaris Partners [4][5] - The addition of Schulman is expected to support Elevance's growth in its Carelon health services division, which includes its pharmacy benefit manager, CarelonRx [7][8] Company Strategy - Elevance is focusing on building its board with experienced professionals from the pharmaceutical industry to strengthen its service offerings [3][8] - The company aims to expand its pharmacy services, particularly through the Carelon division, which was rebranded in 2022 [7] Executive Background - Amy Schulman has held senior roles at Pfizer, including general counsel and president of Pfizer Nutrition, and has significant governance experience [5][6] - Her expertise in the intersection of science, technology, and patient care is seen as a valuable asset for Elevance [8]